Ocugen's OCU410 shows 46% lesion reduction in Phase 2 trial for geographic atrophy
Ocugen's experimental treatment for geographic atrophy, OCU410, has shown promising early results. A Phase 2 trial revealed a 46% reduction in lesion growth, with no serious side effects reported. The news comes as the company's stock price remains volatile, drawing both optimism and scepticism from investors.
The Phase 2 findings for OCU410 highlight its potential in slowing the progression of geographic atrophy, a condition affecting two to three million patients worldwide. This large patient pool suggests significant commercial opportunities for Ocugen if the drug gains approval. Meanwhile, the company's stock has surged by over 342% in the past year, though its current share price sits at $1.99, reflecting ongoing uncertainty.
Analysts remain divided on Ocugen's prospects. Canaccord Genuity's Whitney Ijem recently initiated coverage with a 'buy' rating and a $12 price target, citing strong clinical data. However, short interest has climbed to more than 16% of the float, with nearly 51 million shares sold short—a clear sign of investor scepticism.
The company's next steps include releasing topline data from the Phase 3 LiMeliGhT study for OCU400, a separate candidate, and filing a Biologics License Application (BLA) in Q3 2026. Until these milestones are reached, Ocugen's stock is expected to stay volatile, with Wall Street's average price target currently at $7.
Ocugen's future hinges on regulatory progress and further clinical results. The Phase 2 success of OCU410 offers hope, but investor confidence will likely depend on upcoming data and approvals. For now, the stock remains a high-risk, high-reward prospect in the eyes of analysts and traders alike.
